Home › Cempra, Inc. Receives U.S. Orphan Drug Designation For Taksta For Treatment Of Prosthetic Joint Infections
 

Keywords :   


Cempra, Inc. Receives U.S. Orphan Drug Designation For Taksta For Treatment Of Prosthetic Joint Infections

2013-10-30 05:42:32| drugdiscoveryonline News Articles

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate Taksta™ (CEM-102) for the treatment of prosthetic joint infections (PJI)

Tags: treatment drug joint receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Farm Progress America, May 20, 2024
20.05Farm Progress America, May 20, 2024
20.05Nielsen launches The Media Distributor Gauge
20.05Minerva AI Companion enhances the TV viewing experience
20.05Ryanair profits surge after fares climb by 20%
20.05SES Ethiosat delivering content to 95% of TV homes in Ethiopia
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
More »